Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
← catalyst calendarNCT07397338 · readout ≤ 1,016 d
Sponsored by Revolution Medicines, Inc. (industry) · RVMD — their whole pipeline →. With Summit Therapeutics.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
370estimated
Sites
9
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-30 | actual | When the study began enrolling |
| Primary completion | May 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumors
- Metastatic Solid Tumors
- Non-small Cell Lung Cancer (NSCLC)
- NSCLC
- Colorectal Cancer (CRC)
- CRC
Interventions
- Drug: Daraxonrasib
- Drug: Elironrasib
- Drug: Zoldonrasib
- Drug: Ivonescimab
- Drug: Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)
- Drug: cetuximab (Cohort C2 Only)
- Drug: Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only)
- Drug: Daraxonrasib (Cohort B1 only)
Primary outcomes
what the primary-completion date above is the date OFNumber of patients with adverse events (AEs)
measured Up to approximately 4 years
Changes in vital signs
measured Up to approximately 4 years
Changes in clinical laboratory test values
measured Up to approximately 4 years
Dose Limiting Toxicities
measured 28 days
Permalink · RVMD's whole pipeline · Catalyst calendar · Every registered study · What changed